1. Home
  2. SLRC vs PHAR Comparison

SLRC vs PHAR Comparison

Compare SLRC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRC
  • PHAR
  • Stock Information
  • Founded
  • SLRC 2007
  • PHAR 1988
  • Country
  • SLRC United States
  • PHAR Netherlands
  • Employees
  • SLRC N/A
  • PHAR N/A
  • Industry
  • SLRC Finance/Investors Services
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLRC Finance
  • PHAR Health Care
  • Exchange
  • SLRC Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • SLRC 889.2M
  • PHAR 951.7M
  • IPO Year
  • SLRC 2010
  • PHAR N/A
  • Fundamental
  • Price
  • SLRC $16.07
  • PHAR $14.44
  • Analyst Decision
  • SLRC Hold
  • PHAR Strong Buy
  • Analyst Count
  • SLRC 6
  • PHAR 3
  • Target Price
  • SLRC $16.13
  • PHAR $30.00
  • AVG Volume (30 Days)
  • SLRC 196.3K
  • PHAR 12.7K
  • Earning Date
  • SLRC 11-05-2025
  • PHAR 10-23-2025
  • Dividend Yield
  • SLRC 10.22%
  • PHAR N/A
  • EPS Growth
  • SLRC N/A
  • PHAR N/A
  • EPS
  • SLRC 1.63
  • PHAR N/A
  • Revenue
  • SLRC $222,445,000.00
  • PHAR $339,836,000.00
  • Revenue This Year
  • SLRC N/A
  • PHAR $16.63
  • Revenue Next Year
  • SLRC $0.23
  • PHAR $6.77
  • P/E Ratio
  • SLRC $9.86
  • PHAR N/A
  • Revenue Growth
  • SLRC N/A
  • PHAR 22.44
  • 52 Week Low
  • SLRC $13.64
  • PHAR $7.31
  • 52 Week High
  • SLRC $17.94
  • PHAR $17.08
  • Technical
  • Relative Strength Index (RSI)
  • SLRC 40.78
  • PHAR 54.40
  • Support Level
  • SLRC $15.86
  • PHAR $13.63
  • Resistance Level
  • SLRC $16.15
  • PHAR $15.27
  • Average True Range (ATR)
  • SLRC 0.20
  • PHAR 0.97
  • MACD
  • SLRC -0.08
  • PHAR -0.14
  • Stochastic Oscillator
  • SLRC 20.89
  • PHAR 37.01

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: